# reload+after+2024-01-20 09:44:08.139780
phone§(414) 765-5586
longBusinessSummary§The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
maxAge§86400
priceHint§2
yield§0.0
totalAssets§13934943
navPrice§13.3014
currency§USD
category§Health
ytdReturn§-0.0096511
beta3Year§0.78
fundFamily§Loncar Investments
fundInceptionDate§1444694400
legalType§Exchange Traded Fund
threeYearAverageReturn§-0.2321714
fiveYearAverageReturn§-0.057202302
exchange§NGM
quoteType§ETF
shortName§Range Cancer Therapeutics ETF
longName§Loncar Cancer Immunotherapy ETF
firstTradeDateEpochUtc§1444829400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4f436133-24fa-3b1f-bff4-43d556ecff32
gmtOffSetMilliseconds§-18000000
trailingPegRatio§None
